Talk:Paul-Peter Tak

13-JAN-2018
Dear Wiki team

My name is Nicole and I'm working with Paul-Peter Tak who's asked me to request some factual pages to his Wikipedia page to keep it update.

Requests are below in bold. I you need any additional information I'd be happy to provide.

Paul-Peter Tak is an immunologist, academic and entrepreneur. As a Venture Partner at Flagship Pioneering [– BIOCENTURY – referencing Flagship Pioneering] and previously as Chief Immunology Officer and Development Lead [– BIOCENTURY – referencing Development Lead role] for GSK, Tak combines academic research and clinical practice to inform and develop commercial applications in the field of immunotherapy.[1] Request to add in reference [- THE ACADEMY OF MEDICAL SCIENCES – for additional reference]

Tak has pioneered preclinical and clinical research on the role of the vagus nerve in chronic inflammation.[2] This work provided a platform from which to explore bioelectronics as a therapeutic approach in autoimmune disease. He was also the first to evaluate the effects of a biologic (rituximab) to delay the development of rheumatoid arthritis in individuals at risk of this disease. [- AMERICAN COLLEGE OF RHEUMATOLOGY - referencing rheumatoid arthritis] Recommended reference [- Reference] -  BMJ Journals – additional reference

Tak is currently Venture Partner at Flagship Pioneering and was previously Senior Vice President [– BIOCENTURY – referencing Flagship Pioneering], Chief Immunology Officer and Development Lead [– BIOCENTURY – referencing Development Lead role] for GSK. He has created GSK’s [– E MED EVENTS – referencing GSK] Immunology Network, a collaboration between GSK and several international universities, which offers leading academics access to GSK’s research and development facilities.[3] In addition, Tak is a director of several pharmaceutical start-up companies and a Fellow of the Academy of Medical Sciences.[4]

Academic positions

Please could we add the referenced sections in bold

Following his MD degree, Tak became a research fellow in translational research [- EUREKA INSTITUTE - referencing ‘Translational’ addition] in rheumatology and immunology at Leiden University Medical Center in the Netherlands.[1] Developing a specialism in rheumatology, he has had numerous visiting professorships at institutions including the universities of Kansas, Liverpool, Manitoba, Regensburg, Hong Kong and the William Harvey Institute in London.[6] He was the founding Director of the Department of Clinical Immunology & Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC) and is currently Professor of Medicine at AMC, Honorary Professor of Rheumatology at Ghent University and Honorary Senior Visiting Fellow at the University of Cambridge.

He is also known for his studies on the earliest stages of rheumatoid arthritis as well as [- FUTURE MEDICINE – referencing earliest stages of rheumatoid arthritis] synovial biopsy and synovial tissue analysis;[10] he showed that a reduction in the number of synovial sublining macrophages correlates with a decrease in disease activity in rheumatoid arthritis.[11] This is considered a leading candidate for a viable biomarker of therapeutic response in rheumatoid arthritis.[12]

Commercial roles

Please could we add the referenced section in bold

Within GSK his clinical and research skills meant that Tak has had a presence, as member or chair, on many of their key groups including as chair of the Scientific Review Board [– ACADEMY OF MEDICAL SCIENCES – referencing role as Chair].[5]

Publications

Please could we add the referenced sections in bold to the publication sections

Gerlag DM, Safy M, Maijer KI, Tang MW, Tas SW, Starmans-Kool MJF, van Tubergen A, Janssen M, de Hair M, Hansson M, de Vries N, Zwinderman AH, Tak PP. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann Rheum Dis. 2018 Dec 1. pii: annrheumdis-2017-212763. doi: 10.1136/annrheumdis-2017-212763. [Epub ahead of print]

— Preceding unsigned comment added by Nicole Alston 85 (talk • contribs) 12:47, 14 January 2019 (UTC)

Reply 13-JAN-2019
If there are any areas where mistakes in information were not removed or inadvertently introduced, or if you have any other questions or concerns, please advise. Thank you. Regards,  Spintendo   14:09, 14 January 2019 (UTC)
 * The article has been edited to cleanup the prose and to remove much which was promtional or referenced by primary sources when other sources ought to have been used.
 * All article topics must be verifiable with independent, third-party sources. The cleanup has attempted to balance the WP:WEIGHT of the subject's claims along with the existence of these other sources. In instances where this could not be achieved, text was omitted.
 * The subject's entreprenurial efforts have likewise been omitted. An article should not be a complete exposition of all possible details, but rather, a summary of accepted knowledge regarding its subject. In areas where information about the subject was referenced only by the subject or through publications connected to the subject through the medical/publishing industry, these claims have been omitted. News items concerning the subject ought to originate in sources which are unconnected to the medical industry, mostly because the article already has a great too many sources from this area.
 * The subject's publication section is strong, and is evidence of the subject's many accomplishments in the field of research. That section has been enhanced by including DOI's with the listings.

UDP
I'm cleaning it up myself, but for transparency: This article was created and almost exclusively edited by a UPE sockfarm. Please see Sockpuppet investigations/Jaktheladz/Archive. Thanks and best, --Blablubbs | talk 10:25, 17 March 2021 (UTC)